95 results about "Endothelin I" patented technology

A compound of the formula (I):or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

The invention relates to a composition of plant extracts and application thereof in skin whitening and moisture preservation. The composition comprises the following active ingredients in percentage by weight: 5 to 90 percent of green tea extract, 5 to 50 percent of ginkgo leaf extract and 5 to 45 percent of centella extract, wherein the composition accounts for 0.5 to 20 percent when applied to preparing external products of skin, and the composition is uniformly mixed with medically-acceptable excipients or carriers in proportion to prepare products in forms of gel, cream, serosity, aqueous solution agents, emulsions or solids. The composition has the effects on skin whitening and moisture preservation without adding moisture preserving components; compared with products with similar application, the composition has stronger effects on skin whitening and moisture preservation and smaller dosage; the composition is safe, has no toxic or side effect, has low allergy rates and inflammation probability, penetrates into skin dermis, does not change the normal apoptosis process of cells, restrains tyrosinase, dopachrome tautomerase, DHICA oxidase and endothelin appropriately and balances the metabolism of melanin, so that the color and luster of the skin is more natural; and in addition, the generated skin whitening effect is definite, and the composition is convenient to use in cosmetics.

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.

The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

Described herein is an in vitro method for the determination of the formation of endothelins in serious diseases, in particular cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient, in which relatively long-lived peptide fragments of the processed primary prepro- or proendothelins are determined which contain neither the actual biologically active endothelin nor its direct precursor big endothelin. In particular, disclosed are antibodies and kits for selectively detecting these fragments.

Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and / or cyclophosphamide).

Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.

The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for improving the endothelium function of blood vessels. The traditional Chinese medicine composition of the invention can effectively decrease plasma endothelin (ET) of patients with heart failure, improve the level of nitric oxide (NO) and calcitonin gene-related peptide (CGRP); the traditional Chinese medicine composition of the invention can effectively improve the endothlelium function of blood vessels of patients with chronic heart failure, and the symptoms of heart failure and degree thereof are also reduced with the improvement of the endothelium function of blood vessels.

The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.

A novel targeting peptide from the C-terminal of endothelin and / or a novel fusogenic peptide from hemagglutinin are optionally conjugated to the carboxy group of 1,2-dioleoyl-sn-glycero-3-succinate and incorporated into liposomes for therapeutic treatment. The novel targeting peptide directs liposomes to lung cells, and, therefore, is useful for delivering liposomes encapsulating cholinesterase genes, particularly, the human serum butyryl cholinesterase (Hu BChE) gene, as a treatment against nerve agents. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR §1.72(b).